Stock Report

All about this stock under one free report Last Updated: 26-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Morepen Lab Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: MOREPENLAB | BSE: 500288

₹120.38

up-down-arrow ₹3.78 (3.24%)

As on 25-Sep-2026IST

Market cap

info icon

₹6,600 Cr

Revenue (TTM)

info icon

₹1,951 Cr

P/E Ratio

info icon

47

P/B Ratio

info icon

5.1

Div. Yield

info icon

0.2 %

Edit peer-selector-edit
Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 6,600 36,902 28,103 16,761 15,213
Revenue (₹ Cr)
 1,951 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 140.59 1,018.97 497.77 603.02 270.18
Net Margin (%)
 7.13 10.47 20.72 22.63 23.29
RoE (%)
 9.61 21.30 28.49 19.61 14.45
Price to Earnings
 46.97 36.49 56.46 27.79 55.25
Price-To-Book
 5.07 7.05 13.90 4.81 7.34

Income Statement (₹ Cr)

Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
1,950.58 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
1,972.67 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
1,766.59 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
183.99 1,943.92 762.90 836.69 388.38
Depreciation arrow
35.76 425.10 98.11 78.88 74.78
EBIT arrow
148.24 1,518.82 664.79 757.81 313.60
Interest arrow
17.22 148.45 26.33 5.43 0.26
Other Income arrow
22.09 47.39 30.80 73.83 51.50
Exceptional Items arrow
25.83 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
178.93 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
38.35 370.94 171.48 197.53 91.39
Profit after Tax arrow
140.59 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
1,246.44 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.05 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
198.73 723.57 345.47 142.73 50.51
Current Liabilities arrow
490.30 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
1,936.12 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
623.04 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
1,163.62 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
1,936.12 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
194.69 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
673.31 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
335.40 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
32.64 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-123.42 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
97.40 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
6.62 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
10.19 25.25 27.50 24.61 18.04
ROE (%) arrow
9.61 21.30 28.49 19.61 14.45
ROA (%) arrow
7.57 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
7.60 15.68 28.03 29.25 28.29
Net Margin (%) arrow
7.13 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
9.48 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
29.64 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
50.76 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
26.81 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
7.80 11.36 22.95 18.43 11.27

Valuation Ratios

 Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
56.21 35.74 56.46 26.91 54.76
Price / Book Value arrow
5.07 7.05 13.90 4.81 7.34
Dividend Yield (%) arrow
0.17 0.19 0.16 0.37 0.52
EV/EBITDA arrow
36.43 19.53 36.63 19.10 38.10
Market Cap (₹ Cr) arrow
1,851.92 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.11 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.03 0.16 -- -- --
Current Ratio arrow
2.37 1.43 2.09 5.21 7.39
Quick Ratio arrow
1.82 0.82 1.37 3.85 5.46
Interest Coverage arrow
11.39 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Morepen Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
17.08 26.46 22.82 41.42 41.52
Asset Turnover arrow
1.05 1.09 0.93 0.70 0.52
Receivable days arrow
66.49 88.68 77.32 144.58 169.86
Inventory Days arrow
57.79 84.11 80.83 96.67 97.92
Payable days arrow
116.46 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
7.82 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...